Abstract
Our previous studies demonstrated that mean Sm-C levels were significantly lower in growth-retarded children than normally-growing children with IBD (Gastroenterology 80:1192, 1981). We now report longitudinal data in 10 previously untreated growth-retarded children with CD, followed x̄=17.7 mos. Patients: 5F and 5M, x̄ age 13.2 yrs., all ↓ > 1 major height %ile line with 6 of 10 pts. ≤ 5th %ile for age, Tanner stage I or II. Seven of 10 pts. received daily prednisone (x̄=2 mos) after the initial tests. Methods: Measurements of growth velocity (cm/mo), Sm-C by RIA, calorie intake (72 hr. food diaries) and serum albumin were obtained at the onset of therapy and avg. of 5 times during the follow-up period. Sm-C levels were drawn ≥ 24 hrs. after the previous prednisone dose.
Conclusions: Pts. with ↓ growth had Sm-C levels < those observed during periods of normal growth (p < 0.002). Sm-C rose by 345% and preceded changes in growth velocity & pubertal stage. Concurrently, cal. intake ↑ from 44% to 102% of RDA for ht. age. Fluctuations in Sm may contribute to changes in growth in IBD pts.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirschner, B., Sutton, M. LONGITUDINAL STUDIES OF SOMATOMEDIN-C (SM-C) IN GROWTH-RETARDED CHILDREN WITH CROHN'S DISEASE (CD). Pediatr Res 18 (Suppl 4), 202 (1984). https://doi.org/10.1203/00006450-198404001-00655
Issue Date:
DOI: https://doi.org/10.1203/00006450-198404001-00655